News

/
/
EUnetHTA joint rapid assessment on sorafenib (Nexavar®) and its use as a treatment of thyroid carcinoma

EUnetHTA joint rapid assessment on sorafenib (Nexavar®) and its use as a treatment of thyroid carcinoma

The joint rapid assessment of WP5 Strand A evaluates ‘sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine’ is available.

Find the joint rapid assessment here.

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.